课题基金 / 基金详情

Targeting the Immune System in Mouse Models of Lung Adenocarcinoma

Targeting the Immune System in Mouse Models of Lung Adenocarcinoma
靶向肺腺癌小鼠模型中的免疫系统
批准号:
9055670
负责人:
Susan M Kaech
金额:
$59.19万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-16 至 2018-03-31

项目摘要

项目成果

Susan M Kaech的其他基金

相关文献

中文摘要
翻译
 描述(由申请人提供):癌症免疫治疗正在成为治疗实体瘤的有用策略,并可能成为未来许多肿瘤治疗方案的核心。我们建议将成熟的肺腺癌(LUAD)基因工程小鼠(GEM)模型作为肿瘤免疫微环境表型的工具,并测试和设计结合免疫疗法的治疗干预措施,以优先考虑临床试验的研究。 LUAD是一种破坏性疾病,5年生存率为16.8%(SEER数据2004-2010)。这些令人沮丧的数据强调了对治疗这种疾病的新的、变革性方法的需求。在过去的十年中,出现了两种类型的治疗方法,有可能显着提高LUAD患者的生存率:靶向治疗和免疫治疗。事实上,我们对LUAD分子遗传学的理解的进步已经导致在>60%的LUAD中鉴定出“驱动”癌基因中的突变。使用特定的小分子激酶抑制剂如厄洛替尼(EGFR)和克唑替尼(EML 4-ALK)已成功靶向这些突变体亚组的蛋白质产物,这些抑制剂在临床上常规用于治疗患者。然而,靶向治疗受到几乎不可避免的耐药性发展的限制,平均在开始治疗的一年内。因此,有必要找到优化靶向治疗的方法和/或找到治疗疾病的新方法。 使用癌症免疫疗法调节免疫细胞功能也可以引起抗肿瘤反应,并且正在成为治疗晚期肺癌的有希望的方法。由于这些疗法正在开发和测试用于临床,因此有必要确定谁可能对这些药物产生反应以及如何优化其在临床中的使用。在这里,我们建议验证GEM模型的LUAD代表的主要分子子集的疾病的免疫肿瘤学研究。为此,我们将:1)表征由常见体细胞遗传改变诱导的LUAD GEM模型中的免疫微环境,2)建立免疫系统组分在LUAD GEM模型中对肿瘤发生和肿瘤消退的功能作用,以及3)使用LUAD GEM模型来评估和优化癌症免疫疗法的功效。 这些研究将使我们全面了解LUAD中的免疫微环境,并使我们能够识别可用于治疗干预的漏洞。此外,这项工作将使我们能够开发可以传播的试剂和测定,以标准化GEM的分析和使用,用于NCI肿瘤模型论坛内外的癌症免疫治疗评估。
英文摘要
 DESCRIPTION (provided by applicant): Cancer immunotherapy is emerging as a useful strategy to treat solid tumors and is likely to become central to many oncology treatment regimens in the future. We propose to credential well-established genetically engineered mouse (GEM) models of lung adenocarcinoma (LUAD) as tools to phenotype the tumor immune microenvironment and to test and design therapeutic interventions that incorporate immunotherapies with the objective of prioritizing studies for clinical testing. LUAD is a devastating disease with a 16.8% 5-year survival rate (SEER data 2004-2010). These dismal data underscore the need for novel, transformational approaches to treat this disease. During the past decade, two types of therapeutic approaches have emerged that have the potential to significantly improve survival for patients with LUAD: targeted therapies and immunotherapies. Indeed, advances in our understanding of the molecular genetics of LUAD, have led to the identification of mutations in "driver" oncogenes in >60% of LUADs. The protein products of a subset of these mutants have been successfully targeted using specific small molecule kinase inhibitors such as erlotinib (EGFR) and crizotinib (EML4-ALK) and these are routinely used in the clinic to treat patients. Targeted therapies, however, are limited by the almost inevitable development of drug resistance on average within a year of starting treatment. Therefore, it is necessary to find ways of optimizing the use of targeted therapies and/or finding new ways of treating the disease. Modulation of immune cell function using cancer immunotherapies can also evoke anti-tumor responses and is emerging as a promising approach to treat advanced lung cancer. As these therapies are being developed and tested for clinical use, it is necessary to determine who is likely to respond to these agents and how to optimize their use in the clinic. Here, we propose to validate GEM models of LUAD representing the main molecular subsets of the disease for studies of immuno-oncology. To do this, we will: 1) Characterize the immune microenvironment in LUAD GEM models induced by common somatic genetic alterations, 2) Establish the functional role of components of the immune system for tumorigenesis and tumor regression in LUAD GEM models and 3) Use LUAD GEM models to evaluate and optimize the efficacy of cancer immunotherapies. These studies will provide us with a comprehensive understanding of the immune microenvironment in LUAD and allow us to identify vulnerabilities that can be targeted for therapeutic intervention. Further, this work will enable us to develop reagents and assays that can be disseminated to standardize the analysis and use of GEMs for the evaluation of cancer immunotherapies both within and outside of the NCI's Oncology Models Forum.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Infectious history as a determinant of age-related inflammation in Alzheimers disease
Core 1: Tumor and Microenvironment Heterogeneity Core (TMH Core)
Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer
Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer